Research

Research RET Webinar

2026 RET Research Update: What the Experts Shared

The 2026 Annual RET Research Update Webinar brought together leading researchers, clinicians and industry experts…

The Happy Lungs ProjectNovember 8, 2026

Research RET Webinar

2026 RET Webinar: Meet Our Speakers

The 2026 RET Research Update is just around the corner, and we are excited to…

The Happy Lungs ProjectSeptember 30, 2026

Research

New RET Research Advances from IASLC WCLC 2026

IASLC World Conference on Lung Cancer (WCLC) 2026 featured important new research advancing the understanding…

Irene Guijarro MunozSeptember 16, 2026

Biomarker Testing Nino's News Research

RET-Fusion Positive NSCLC: Why Genomic Testing Matters for Your Treatment

Advances in biomarker science are reshaping how patients are diagnosed with and manage early-stage lung…

Irene Guijarro MunozAugust 18, 2026

RET inhibitor and chemotherapy treatment for lung cancer

Research Treatment

Continuing a RET Inhibitor With Chemotherapy After Progression May Improve Outcomes For RET Lung Cancer Patients

RET Inhibitor with chemotherapy after progression may improve outcomes for RET lung cancer patients

Irene Guijarro MunozJuly 10, 2026

Research

New FOXM1 T cell therapies that can target RET tumors

Researchers at MD Anderson Cancer Center have found that RET lung cancers have unusually high…

Irene Guijarro MunozJune 24, 2026

Research

What the New NCCN Guidelines Mean for RET+ Lung Cancer

The recent NCCN Guideline update represents an important advancement in the treatment of early-stage NSCLC.

Irene Guijarro MunozJune 19, 2026

Research

RET Highlights Presented at the 2026 American Society of Clinical Oncology (ASCO)

The ASCO Annual Meeting 2026, held in Chicago, brought together oncology experts, researchers, healthcare professionals,…

Irene Guijarro MunozJune 12, 2026

Research

ASCO 2026: Selpercatinib Shows Strong Results in Early-Stage RET+ Lung Cancer

Results support the use of selpercatinib in the early-stage setting and highlight the need for…

Irene Guijarro MunozJune 3, 2026

2026 AACR annual meeting RET cancer findings

Research

New AACR 2026 Findings on TP53 Co-Mutations and RET Fusion Partners in RET+ NSCLC

New research from the 2026 AACR Annual Meeting shows that certain co-mutations and fusion partners…

Irene Guijarro MunozMay 27, 2026

2026 RET Research Update: What the Experts Shared

2026 RET Webinar: Meet Our Speakers

New RET Research Advances from IASLC WCLC 2026

RET-Fusion Positive NSCLC: Why Genomic Testing Matters for Your Treatment

Continuing a RET Inhibitor With Chemotherapy After Progression May Improve Outcomes For RET Lung Cancer Patients

New FOXM1 T cell therapies that can target RET tumors

What the New NCCN Guidelines Mean for RET+ Lung Cancer

RET Highlights Presented at the 2026 American Society of Clinical Oncology (ASCO)

ASCO 2026: Selpercatinib Shows Strong Results in Early-Stage RET+ Lung Cancer

New AACR 2026 Findings on TP53 Co-Mutations and RET Fusion Partners in RET+ NSCLC

Popular Posts

Scientific research can be confusing and overwhelming